JPH11510688A - パピローマウイルスのポリプロテイン構築物 - Google Patents

パピローマウイルスのポリプロテイン構築物

Info

Publication number
JPH11510688A
JPH11510688A JP9507011A JP50701197A JPH11510688A JP H11510688 A JPH11510688 A JP H11510688A JP 9507011 A JP9507011 A JP 9507011A JP 50701197 A JP50701197 A JP 50701197A JP H11510688 A JPH11510688 A JP H11510688A
Authority
JP
Japan
Prior art keywords
sequence
polyprotein
polyprotein construct
construct
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9507011A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11510688A5 (2
Inventor
アン ウェブ，エリザベス
ブリジッド マーゲッツ，メアリー
クーパー コックス，ジョン
フレーザー，イアン
アラン ジョン マクミリアン，ニーゲル
フィリップ ウイリアムズ，マーク
ブリジェット ホランド モロニイ，マーガレット
ジョン エドワーズ，スターリング
Original Assignee
シーエスエル、リミテッド
ザ、ユニバーシティ、オブ、クイーンズランド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエスエル、リミテッド, ザ、ユニバーシティ、オブ、クイーンズランド filed Critical シーエスエル、リミテッド
Publication of JPH11510688A publication Critical patent/JPH11510688A/ja
Publication of JPH11510688A5 publication Critical patent/JPH11510688A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP9507011A 1995-07-27 1996-07-26 パピローマウイルスのポリプロテイン構築物 Ceased JPH11510688A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU4439 1995-07-27
AUPN4439A AUPN443995A0 (en) 1995-07-27 1995-07-27 Papillomavirus polyprotein
PCT/AU1996/000473 WO1997005164A1 (en) 1995-07-27 1996-07-26 Papillomavirus polyprotein constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006285406A Division JP2007054074A (ja) 1995-07-27 2006-10-19 パピローマウイルスのポリプロテイン構築物

Publications (2)

Publication Number Publication Date
JPH11510688A true JPH11510688A (ja) 1999-09-21
JPH11510688A5 JPH11510688A5 (2) 2004-08-12

Family

ID=3788774

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9507011A Ceased JPH11510688A (ja) 1995-07-27 1996-07-26 パピローマウイルスのポリプロテイン構築物
JP2006285406A Withdrawn JP2007054074A (ja) 1995-07-27 2006-10-19 パピローマウイルスのポリプロテイン構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006285406A Withdrawn JP2007054074A (ja) 1995-07-27 2006-10-19 パピローマウイルスのポリプロテイン構築物

Country Status (8)

Country Link
US (2) US6365160B1 (2)
EP (2) EP1847549A3 (2)
JP (2) JPH11510688A (2)
AU (1) AUPN443995A0 (2)
CA (1) CA2228221C (2)
NZ (1) NZ313108A (2)
WO (1) WO1997005164A1 (2)
ZA (1) ZA966381B (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525613A (ja) * 2000-09-30 2004-08-26 ヤン シェン タン イオン シィエン クゥオン ス Ｅ型肝炎ウイルスのポリペプチド断片、それを含むワクチン組成物及び診断キット、並びにその使用
JP2012507293A (ja) * 2008-10-31 2012-03-29 トローバジーン インコーポレイテッド ヒトパピローマウイルスを検出するための遺伝子マーカー
JP2023550480A (ja) * 2020-11-25 2023-12-01 プレシゲン，インコーポレイテッド ヒト乳頭腫ウイルスワクチンおよびｈｐｖ関連疾患のための同ワクチンの使用

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides
US6030771A (en) * 1997-08-25 2000-02-29 Centers For Disease Control And Prevention Mosaic protein and restriction endonuclease assisted ligation method for making the same
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP1728865A1 (en) * 1998-09-04 2006-12-06 Aventis Pasteur Limited Treatment of cervical cancer
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
ES2317910T3 (es) * 2000-07-06 2009-05-01 Georgetown University Formas (fijas) estables e proteinas de capside l1 virales, proteinas de fusion y sus utilizaciones.
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
AU2003215244A1 (en) * 2002-02-14 2003-09-04 Curagen Corporation Complexes and methods of using same
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2002950183A0 (en) * 2002-07-12 2002-09-12 The Council Of The Queensland Institute Of Medical Research Expression of hydrophobic proteins
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
MXPA05003395A (es) * 2002-10-03 2005-06-22 Wyeth Corp Polipeptidos de virus de papiloma humano y composiciones inmunogenas.
DE60332377D1 (de) * 2002-10-21 2010-06-10 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
WO2004105681A2 (en) * 2003-04-28 2004-12-09 Innogenetics N.V. Cd4+ human papillomavirus (hpv) epitopes
US20080160089A1 (en) * 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
JP5192384B2 (ja) 2005-09-22 2013-05-08 メディバス エルエルシー ビス−（α−アミノ）−ジオール−ジエステル含有ポリ（エステルアミド）およびポリ（エステルウレタン）組成物および使用の方法
CA2623239C (en) * 2005-09-22 2016-07-12 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
JP2009524584A (ja) * 2005-12-07 2009-07-02 メディバス エルエルシー ポリマー−生物製剤送達組成物を構築するための方法
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CA2649672C (en) * 2006-05-02 2015-07-07 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
KR100904844B1 (ko) * 2006-08-28 2009-06-25 성균관대학교산학협력단 인유두종 바이러스（ｈｐｖ）유전자를 포함하는자궁경부암의 치료 또는 예방용 ｄｎａ 백신
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20090029937A1 (en) * 2007-07-24 2009-01-29 Cornell University Biodegradable cationic polymer gene transfer compositions and methods of use
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2733686A1 (en) * 2008-08-13 2010-02-18 Medivas, Llc Aabb-poly(depsipeptide) biodegradable polymers and methods of use
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US9050287B2 (en) * 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
US9963549B2 (en) 2011-06-23 2018-05-08 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
CN114277038A (zh) * 2011-10-12 2022-04-05 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的疫苗及其使用方法
WO2014165291A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
EP3233067B1 (en) 2014-12-18 2019-11-06 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs
WO2019173465A1 (en) 2018-03-06 2019-09-12 Intrexon Corporation Human papillomavirus vaccines and uses of the same
US12577398B2 (en) 2019-11-12 2026-03-17 Dsm Ip Assets B.V. Polyesteramide copolymers possessing high glass transition temperatures

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
EP0451550A3 (en) * 1990-03-20 1991-11-06 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
DE4015044A1 (de) * 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
CN1067382A (zh) * 1990-09-26 1992-12-30 布里斯托尔-迈尔斯斯奎尔公司 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用
KR100252371B1 (ko) * 1990-12-12 2000-05-01 포터 더글라스 서브유니트 파필로마비루스 백신 및 그들에 사용하기 위한 펩티드
US5464936A (en) 1990-12-21 1995-11-07 Cetus Oncology Corporation Compositions for identification of papillomavirus replication inhibitors
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
GB9207701D0 (en) * 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
WO1994012629A1 (en) * 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
CA2195642A1 (en) * 1994-07-27 1996-02-08 Andreas Suhrbier Polyepitope vaccines
DE4435907C2 (de) 1994-10-07 1997-07-24 Lutz Prof Dr Gissmann Papillomavirusähnliche Partikel und deren Anwendung
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
US5955087A (en) * 1995-02-24 1999-09-21 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525613A (ja) * 2000-09-30 2004-08-26 ヤン シェン タン イオン シィエン クゥオン ス Ｅ型肝炎ウイルスのポリペプチド断片、それを含むワクチン組成物及び診断キット、並びにその使用
US8715695B2 (en) 2000-09-30 2014-05-06 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Polypeptide fragments of the hepatitis E virus, the vaccine composition comprising said fragments and the diagnostic kits
JP2012507293A (ja) * 2008-10-31 2012-03-29 トローバジーン インコーポレイテッド ヒトパピローマウイルスを検出するための遺伝子マーカー
JP2015130863A (ja) * 2008-10-31 2015-07-23 トローバジーン インコーポレイテッド ヒトパピローマウイルスを検出するための遺伝子マーカー
JP2023550480A (ja) * 2020-11-25 2023-12-01 プレシゲン，インコーポレイテッド ヒト乳頭腫ウイルスワクチンおよびｈｐｖ関連疾患のための同ワクチンの使用

Also Published As

Publication number Publication date
AUPN443995A0 (en) 1995-08-17
EP0840747A4 (en) 2002-10-23
CA2228221C (en) 2011-05-17
CA2228221A1 (en) 1997-02-13
US6365160B1 (en) 2002-04-02
EP0840747A1 (en) 1998-05-13
ZA966381B (en) 1997-05-02
US6726912B1 (en) 2004-04-27
NZ313108A (en) 1999-05-28
WO1997005164A1 (en) 1997-02-13
JP2007054074A (ja) 2007-03-08
EP1847549A3 (en) 2008-01-16
EP1847549A2 (en) 2007-10-24

Similar Documents

Publication Publication Date Title
JPH11510688A (ja) パピローマウイルスのポリプロテイン構築物
US5618536A (en) Chimeric papillomavirus-like particles
JP5296665B2 (ja) ヒトパピローマウイルスカプソメアワクチン製剤の製造方法
CA2207741C (en) Variants of human papilloma virus antigens
JP3958360B2 (ja) 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US7691386B2 (en) Chimeric papillomavirus-like particles
US20020197668A1 (en) Papilloma virus capsomere vaccine formulations and methods of use
AU699547B2 (en) Papillomavirus polyprotein constructs
CN105801704A (zh) 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用
AU717647B2 (en) Chimeric papillomavirus-like particles
AU717932B2 (en) Chimeric papillomavirus-like particles
CA2201601C (en) Chimeric papillomavirus-like particles
HK1109907A (en) Papillomavirus polyprotein constructs
KR20000029687A (ko) 면역치료제로서유용한폴리펩티드및폴리펩티드의제조방법
MXPA98001583A (es) Formulaciones para vacunas de capsomero del papiloma virus.

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20041020

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20041206

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20050314

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061019

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061127

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070118

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20070125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081225

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090306